Argenica’s Clinical Trial Progress and Financial Health

Argenica Therapeutics Ltd (AU:AGN) has released an update.

Argenica Therapeutics Ltd has made significant strides in its Phase 2 clinical trial for ARG-007, aimed at treating acute ischaemic stroke, with all hospital sites in Australia now active and patient recruitment halfway completed. Positive safety data supports the continuation of the trial without modifications, and the company is preparing an Investigational New Drug application for the FDA. With cash reserves of $13.9 million and anticipated R&D tax rebates, Argenica remains financially robust as it explores ARG-007’s potential in other neurological conditions.

For further insights into AU:AGN stock, check out TipRanks’ Stock Analysis page.